Skip to main content Help with accessibility Skip to main navigation

Strontium Ranelate

Indication

Primary and secondary prevention of osteoporotic fragility fractures in postmenopausal women
MHRA Drug Safety Update - Strontium ranelate: cardiovascular risk—restricted indication and new monitoring requirements (March 2014)

 

Amber level 0

Brand:

Nice TA:

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Endocrine system

Background

The EMA has considered that strontium ranelate should only be used by people for whom there are no other treatments for osteoporosis. The cardiovascular risks identified with strontium ranelate may be sufficiently reduced in this population by restricting its use to people without cardiovascular contraindications. Please see link to the Drug Safety Update on the MHRA website for further information (in supporting documents below)

Recommendation

LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

Decisions of Lancashire local decision making groups

Pending
Amber 0
Amber 0
Pending
Amber 0
Amber 0
Amber 0
Pending
What do the colours mean?

Last Updated: 01 - Feb - 2016